<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="brief-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Osteoporos Int</journal-id>
      <journal-id journal-id-type="iso-abbrev">Osteoporos Int</journal-id>
      <journal-title-group>
        <journal-title>Osteoporosis International</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0937-941X</issn>
      <issn pub-type="epub">1433-2965</issn>
      <publisher>
        <publisher-name>Springer London</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">23835864</article-id>
      <article-id pub-id-type="pmc">3889627</article-id>
      <article-id pub-id-type="publisher-id">2437</article-id>
      <article-id pub-id-type="doi">10.1007/s00198-013-2437-z</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Neuprez</surname>
            <given-names>A.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
          <xref ref-type="aff" rid="Aff5"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Coste</surname>
            <given-names>S.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rompen</surname>
            <given-names>E.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Crielaard</surname>
            <given-names>J. M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Reginster</surname>
            <given-names>J. Y.</given-names>
          </name>
          <address>
            <email>jyreginster@ulg.ac.be</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
          <xref ref-type="aff" rid="Aff5"/>
          <xref ref-type="aff" rid="Aff6"/>
        </contrib>
        <aff id="Aff1"><label/>Public Health, Epidemiology and Health Economics Department, University of Li&#xE8;ge, Belgium, Li&#xE8;ge, Belgium </aff>
        <aff id="Aff2"><label/>Bone and Cartilage Metabolism Unit, CHU, Li&#xE8;ge, Belgium </aff>
        <aff id="Aff3"><label/>Gynecology Department, CHC St. Joseph, Li&#xE8;ge, Belgium </aff>
        <aff id="Aff4"><label/>Stomatology Department, CHU, Li&#xE8;ge, Belgium </aff>
        <aff id="Aff5"><label/>Motricity Sciences Department, CHU, Li&#xE8;ge, Belgium </aff>
        <aff id="Aff6"><label/>Department of Public Health, Epidemiology and Health Economics, CHU Sart Tilman, Boulevard de l&#x2019;H&#xF4;pital, 3 4000 Li&#xE8;ge, Belgium </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>9</day>
        <month>7</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>9</day>
        <month>7</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2014</year>
      </pub-date>
      <volume>25</volume>
      <issue>1</issue>
      <fpage>393</fpage>
      <lpage>395</lpage>
      <history>
        <date date-type="received">
          <day>30</day>
          <month>5</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>21</day>
          <month>6</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2013</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p>Osteonecrosis of the jaw (ONJ) is a clinical condition associated with long-term exposure to inhibitors of bone resorption, mainly bisphosphonates. Denosumab (DMab) is a human monoclonal antibody of the receptor activator of nuclear factor kappa-B ligand. It prevents osteoclast-mediated bone resorption and is widely prescribed for the management of postmenopausal osteoporosis. Whereas ONJ has already been reported in women treated with DMab, we report for the first time the development of ONJ, following tooth extraction, in a male patient treated for idiopathic osteoporosis with DMab. Due to the constant increase in DMab prescription, for the management of osteoporosis, in both genders, physicians should be made aware of this potential risk.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Denosumab</kwd>
        <kwd>Jaw</kwd>
        <kwd>Osteonecrosis</kwd>
        <kwd>Osteoporosis</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; International Osteoporosis Foundation and National Osteoporosis Foundation 2014</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <p>Osteoporosis is widely considered to be much more prevalent in women even though approximately 39&#xA0;% of new osteoporotic fractures estimated to have occurred worldwide in the year 2000 were in men [<xref ref-type="bibr" rid="CR1">1</xref>]. Men have greater morbidity and mortality rates due to hip fractures compared to women [<xref ref-type="bibr" rid="CR2">2</xref>]. Most of the drugs currently available to treat osteoporosis in women show a similar response in men than that observed in postmenopausal osteoporosis [<xref ref-type="bibr" rid="CR1">1</xref>].</p>
    <p>A 58-year-old Caucasian man was diagnosed with idiopathic, predominantly trabecular, osteoporosis (OP) in June 2012, based on the following:<list list-type="order"><list-item><p>A previous history of three atraumatic rib fractures (2005)</p></list-item><list-item><p>A bone mineral density T-score of &#x2212;2.9 and &#x2212;1.5 at the lumbar spine and femoral neck, respectively</p></list-item><list-item><p>The prevalence of a morphometric vertebral deformity (semi quantitative Grade 2) at T8</p></list-item></list></p>
    <p>Serum 25 (OH) Vitamin D was in the lower range of recommended values [<xref ref-type="bibr" rid="CR3">3</xref>] (60&#xA0;nmol/l) and serum intact parathormone was slightly abnormal at 27&#xA0;pg/ml (normal range, 4&#x2013;26&#xA0;pg/ml) [1&#x2013;84 PTH (DiaSorin, Stillwater, MN, USA] [<xref ref-type="bibr" rid="CR4">4</xref>]. The absolute 10-year fracture risk calculated with the FRAX&#xAE; algorithm was 17 and 3.9&#xA0;% for major osteoporotic and hip fracture, respectively. These values are above the thresholds for therapeutic interventions that were previously published for Belgium [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>].</p>
    <p>All investigations for causes of secondary osteoporosis remained negative. Due to past history of myocardial infarctions (2002 and 2009), hypertension (i.e., controlled with simvastatin), and the suspicion of a potentially poor adherence to oral medications, denosumab (DMab)(Prolia&#xAE;, Amgen) was initiated (July 12) at a dose of 60&#xA0;mg, given subcutaneously every 6&#xA0;months together with daily supplementation of calcium (1&#xA0;g/day) and vitamin D (800&#xA0;IU/day).</p>
    <p>DMab is a human monoclonal antibody of the receptor activator of nuclear factor kappa-B ligand (RANKL). It competes with RANKL for RANK-binding sites, thereby preventing osteoclast-mediated bone resorption [<xref ref-type="bibr" rid="CR7">7</xref>]. DMab is a well-established, widely-prescribed treatment for the management of postmenopausal osteoporosis [<xref ref-type="bibr" rid="CR8">8</xref>].</p>
    <p>It should be noted that despite promising clinical results were published in male patients with low bone mineral density [<xref ref-type="bibr" rid="CR9">9</xref>] and notwithstanding DMab was recently shown to be cost-effective compared to oral bisphosphonates (BP) in osteoporotic men [<xref ref-type="bibr" rid="CR10">10</xref>], this chemical entity is not yet approved nor marketed in Europe for the treatment of osteoporosis in males [<xref ref-type="bibr" rid="CR1">1</xref>].</p>
    <p>During DMab treatment (November 2012), extraction of a right wisdom tooth took (48) place and was followed by a mild, slightly progressive pain in the right mandible. A dentist initiated (December 2012) systemic antibiotherapy (AB) (amoxicillin, 1.5&#xA0;g/day) and antibacterial mouth rinse with no impact on the symptoms.</p>
    <p>The patient was referred to us (April 2013). Clinical examination revealed oral lesions with bone exposure. CT of the right mandible showed an extensive osteolysis, with a sequestrum in the medullary cavity, surrounded by a periosteal thickening, highly suggestive of an osteonecrosis of the jaw (ONJ), subsequent to a mandibular osteomyelitis (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>CT scan of the right mandible revealing osteonecrosis. <bold>a</bold> Sequestrum in the medullary cavity (<italic>white arrow</italic>) and <bold>b</bold> extensive osteolysis of the right mandible (<italic>white arrow</italic>)</p></caption><graphic xlink:href="198_2013_2437_Fig1_HTML" id="MO1"/></fig></p>
    <p>Concomitant malignant tumor was excluded. Treatment included AB coverage, removal of necrotic bone, and treatment with a bone anabolic agent (teriparatide, 20&#xA0;g/day subcutaneously) with the maintenance of a calcium and vitamin D daily supplementation.</p>
    <p>ONJ is a clinical condition that presents as exposed bone in the mandible, maxilla, or both, that persists for at least 8&#xA0;weeks, in the absence of previous radiation and of metastases in the jaw. Whereas no epidemiologic data on the incidence of ONJ in the general population are available, a positive relationship was described between ONJ occurrence and the use of inhibitors of bone resorption (mainly BP) in patients with multiple myeloma, metastatic breast cancer, Paget&#x2019;s disease, osteoporosis, or other skeletal disorders [<xref ref-type="bibr" rid="CR11">11</xref>]. Several pathogenic mechanisms have been proposed. One of them suggests that ONJ can be caused by BP-induced low-bone turnover, which leads to decreased blood flow and bone cell necrosis and apoptosis. In conjunction with chronic oral or dental infection, this leads to the development of exposed, nonhealing bone areas in the mouth [<xref ref-type="bibr" rid="CR12">12</xref>]. The use of inhibitors of bone resorption prevents bone remodeling to ensure the replacement of defective bone with an equivalent volume of healthy bone [<xref ref-type="bibr" rid="CR13">13</xref>].</p>
    <p>DMab was previously related to the development of ONJ, during treatment for sacral giant cell tumor [<xref ref-type="bibr" rid="CR14">14</xref>], metastatic bone disease [<xref ref-type="bibr" rid="CR15">15</xref>], and prostatic adenocarcinoma [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>], the doses of DMab used in metastatic bone diseases being 12 times greater than in the management of OP.</p>
    <p>A recent meta-analysis assessing a total of 8,963 patients of both genders, with a variety of solid tumors, from seven studies (i.e., the majority of these patients had either prostate or breast cancer) revealed an overall incidence of ONJ in cancer patients receiving DMab of 1.7&#xA0;% (95&#xA0;% Cl, 0.9&#x2013;3.1&#xA0;%). This study concluded that, in such patients, the use of DMab is associated with an increased risk of developing ONJ when compared with BP treatment or placebo, although the increased risk was not statistically significant between DMab and BP treatments [<xref ref-type="bibr" rid="CR18">18</xref>].</p>
    <p>In postmenopausal osteoporosis, two cases of ONJ were described in a cohort of 2,207 women treated with 60&#xA0;mg subcutaneously. DMab every 6&#xA0;months, for 2&#xA0;years, after having received a placebo during the previous 3&#xA0;years [<xref ref-type="bibr" rid="CR19">19</xref>].</p>
    <p>In conclusion, we describe for the first time the development of ONJ following tooth extraction, in a male patient, treated for idiopathic osteoporosis with DMab. Due to the constant increase in DMab prescription, for the management of osteoporosis, in both genders, physicians should be made aware of this potential risk.</p>
  </body>
  <back>
    <ack>
      <title>Conflicts of interest</title>
      <p>J.Y. Reginster has received consulting fees or paid advisory boards from Servier, Novartis, Negma, Lilly, Wyeth, Amgen, GlaxoSmithKline, Roche, Merckle, Nycomed, NPS, and Theramex; lecture fees when speaking at the invitation of a commercial sponsor from Merck Sharp and Dohme, Lilly, Rottapharm, IBSA, Genevrier, Novartis, Servier, Roche, GlaxoSmithKline, Teijin, Teva, Ebewee Pharma, Zodiac, Analis, Theramex, Nycomed, and Novo-Nordisk; and grant support from Bristol Myers Squibb, Merck Sharp &amp; Dohme, Rottapharm, Teva, Eli Lilly, Novartis, Roche, GlaxoSmithKline, Amgen, and Servier.</p>
      <p>A. Neuprez received travel grant from Amgen and Servier.</p>
      <p>S. Coste received travel grant from Amgen and Servier.</p>
      <p>E. Rompen has no conflict of interest.</p>
      <p>J.M. Crielaard has no conflict of interest.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaufman</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Reginster</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Boonen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Brandi</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Dere</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Devogelaer</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Diez-Perez</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kanis</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>McCloskey</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Mitlak</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Orwoll</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ringe</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Weryha</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Rizzoli</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Treatment of osteoporosis in men</article-title>
          <source>Bone</source>
          <year>2013</year>
          <volume>53</volume>
          <fpage>134</fpage>
          <lpage>144</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bone.2012.11.018</pub-id>
          <pub-id pub-id-type="pmid">23201268</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaufman</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Goemaere</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Osteoporosis in men</article-title>
          <source>Best Pract Res Clin Endocrinol Metab</source>
          <year>2008</year>
          <volume>22</volume>
          <fpage>787</fpage>
          <lpage>812</lpage>
          <pub-id pub-id-type="doi">10.1016/j.beem.2008.09.005</pub-id>
          <pub-id pub-id-type="pmid">19028357</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rizzoli</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Boonen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Brandi</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Bruy&#xE8;re</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kanis</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Kaufman</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Ringe</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Weryha</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Reginster</surname>
              <given-names>JY</given-names>
            </name>
          </person-group>
          <article-title>Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)</article-title>
          <source>Curr Med Res Opin</source>
          <year>2013</year>
          <volume>29</volume>
          <fpage>305</fpage>
          <lpage>313</lpage>
          <pub-id pub-id-type="doi">10.1185/03007995.2013.766162</pub-id>
          <pub-id pub-id-type="pmid">23320612</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cavalier</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Delanaye</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Moranne</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Variability of new bone mineral metabolism markers in patients treated with maintenance hemodialysis : implications for clinical decision making</article-title>
          <source>Am J Kindey Dis</source>
          <year>2013</year>
          <volume>61</volume>
          <fpage>847</fpage>
          <lpage>848</lpage>
          <pub-id pub-id-type="doi">10.1053/j.ajkd.2012.12.013</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Johansson</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kanis</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>McCloskey</surname>
              <given-names>EV</given-names>
            </name>
            <name>
              <surname>Oden</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Devogelaer</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Kaufman</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Neuprez</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hiligsmann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bruy&#xE8;re</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Reginster</surname>
              <given-names>JY</given-names>
            </name>
          </person-group>
          <article-title>A FRAX&#xB0; model for the assessment of fracture probability in Belgium</article-title>
          <source>Osteoporos Int</source>
          <year>2011</year>
          <volume>22</volume>
          <fpage>453</fpage>
          <lpage>461</lpage>
          <pub-id pub-id-type="doi">10.1007/s00198-010-1218-1</pub-id>
          <pub-id pub-id-type="pmid">20352409</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neuprez</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Johansson</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kanis</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>McCloskey</surname>
              <given-names>EV</given-names>
            </name>
            <name>
              <surname>Oden</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bruy&#xE8;re</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Hiligsmann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Devogelaer</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Kaufman</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Reginster</surname>
              <given-names>JY</given-names>
            </name>
          </person-group>
          <article-title>A FRAX model for the assessment of fracture probability in Belgium</article-title>
          <source>Rev Med Li&#xE8;ge</source>
          <year>2009</year>
          <volume>64</volume>
          <fpage>612</fpage>
          <lpage>619</lpage>
          <pub-id pub-id-type="pmid">20143744</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bekker</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Holloway</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Rasmussen</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Leese</surname>
              <given-names>PT</given-names>
            </name>
            <name>
              <surname>Holmes</surname>
              <given-names>GB</given-names>
            </name>
            <name>
              <surname>Dunstan</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>DePaoli</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
          <article-title>A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women</article-title>
          <source>J Bone Miner Res</source>
          <year>2004</year>
          <volume>19</volume>
          <fpage>1059</fpage>
          <lpage>1066</lpage>
          <pub-id pub-id-type="doi">10.1359/JBMR.040305</pub-id>
          <pub-id pub-id-type="pmid">15176987</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kanis</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>McCloskey</surname>
              <given-names>EV</given-names>
            </name>
            <name>
              <surname>Johansson</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rizzoli</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Reginster</surname>
              <given-names>JY</given-names>
            </name>
          </person-group>
          <article-title>European guidance for the diagnosis and management of osteoporosis in postmenopausal women</article-title>
          <source>Osteoporos Int</source>
          <year>2013</year>
          <volume>24</volume>
          <fpage>23</fpage>
          <lpage>57</lpage>
          <pub-id pub-id-type="doi">10.1007/s00198-012-2074-y</pub-id>
          <pub-id pub-id-type="pmid">23079689</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Orwoll</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Teglbjaerg</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Langdahl</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Chapurlat</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Czerwinski</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kendler</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Reginster</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Kivitz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lewiecki</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Bolognese</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>McClung</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Bone</surname>
              <given-names>HG</given-names>
            </name>
            <name>
              <surname>Ljunggren</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Abrahamsen</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Gruntmanis</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>YC</given-names>
            </name>
            <name>
              <surname>Wagman</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Siddhanti</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Grauer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Boonen</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2012</year>
          <volume>97</volume>
          <fpage>3161</fpage>
          <lpage>3169</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2012-1569</pub-id>
          <pub-id pub-id-type="pmid">22723310</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parthan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kruse</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Agodoa</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Tao</surname>
              <given-names>CY</given-names>
            </name>
            <name>
              <surname>Silverman</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Orwoll</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Is denosumab cost-effective compared to oral bisphosphonates for the treatment of male osteoporosis (mop) in Sweden?</article-title>
          <source>Value Health</source>
          <year>2013</year>
          <volume>16</volume>
          <fpage>A223</fpage>
          <pub-id pub-id-type="doi">10.1016/j.jval.2013.03.1130</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rizzoli</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Burlet</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Cahall</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Delmas</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Eriksen</surname>
              <given-names>EF</given-names>
            </name>
            <name>
              <surname>Felsenberg</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Grbic</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Jontell</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Landesberg</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Laslop</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wollenhaupt</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Papapoulos</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sezer</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Sprafka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Reginster</surname>
              <given-names>JY</given-names>
            </name>
          </person-group>
          <article-title>Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis</article-title>
          <source>Bone</source>
          <year>2008</year>
          <volume>42</volume>
          <fpage>841</fpage>
          <lpage>847</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bone.2008.01.003</pub-id>
          <pub-id pub-id-type="pmid">18314405</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ruggiera</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Mehrotra</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Rosenberg</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Engroff</surname>
              <given-names>SL</given-names>
            </name>
          </person-group>
          <article-title>Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases</article-title>
          <source>J Oral Maxillofac Surg</source>
          <year>2004</year>
          <volume>62</volume>
          <fpage>527</fpage>
          <lpage>534</lpage>
          <pub-id pub-id-type="doi">10.1016/j.joms.2004.02.004</pub-id>
          <pub-id pub-id-type="pmid">15122554</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Subramanian</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>HV</given-names>
            </name>
            <name>
              <surname>Quek</surname>
              <given-names>SY</given-names>
            </name>
          </person-group>
          <article-title>A model for the pathogenesis of bisphosphonate-associated osteonecrosis of the jaw and teriparatide&#x2019;s potential role in its resolution</article-title>
          <source>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</source>
          <year>2011</year>
          <volume>112</volume>
          <fpage>744</fpage>
          <lpage>753</lpage>
          <pub-id pub-id-type="doi">10.1016/j.tripleo.2011.04.020</pub-id>
          <pub-id pub-id-type="pmid">21821444</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aghaloo</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Felsenfeld</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Tetradis</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Osteonecrosis of the jaw in a patient on Denosumab</article-title>
          <source>J Oral Maxillofac Surg</source>
          <year>2010</year>
          <volume>68</volume>
          <fpage>959</fpage>
          <lpage>963</lpage>
          <pub-id pub-id-type="doi">10.1016/j.joms.2009.10.010</pub-id>
          <pub-id pub-id-type="pmid">20149510</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Raylor</surname>
              <given-names>KH</given-names>
            </name>
            <name>
              <surname>Middlefell</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Mizen</surname>
              <given-names>KD</given-names>
            </name>
          </person-group>
          <article-title>Osteonecrosis of the jaws induced by anti-RANK ligand therapy</article-title>
          <source>Br J Oral Maxillofac Surg</source>
          <year>2010</year>
          <volume>48</volume>
          <fpage>221</fpage>
          <lpage>223</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bjoms.2009.08.030</pub-id>
          <pub-id pub-id-type="pmid">19836866</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Diz</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lopez-Cedrun</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Arenaz</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Scully</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Denosumab-related osteonecrosis of the jaw</article-title>
          <source>J Am Dent Assoc</source>
          <year>2012</year>
          <volume>143</volume>
          <fpage>981</fpage>
          <lpage>984</lpage>
          <pub-id pub-id-type="doi">10.14219/jada.archive.2012.0323</pub-id>
          <pub-id pub-id-type="pmid">22942143</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pichardo</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Kuypers</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Van Merkesteyn</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>Denosumab osteonecrosis of the mandible: a new entity? A case report</article-title>
          <source>J Craniomaxillofac Surg</source>
          <year>2013</year>
          <volume>41</volume>
          <fpage>e65</fpage>
          <lpage>e69</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcms.2012.10.014</pub-id>
          <pub-id pub-id-type="pmid">23265807</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <mixed-citation publication-type="other">Qi WX, Tang LN, He AN, Yao Y (2013) Shen Z Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol (in press)</mixed-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Papapoulos</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chapurlat</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Libanati</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Brandi</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Czerwinski</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Krieg</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Man</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Mellstr&#xF6;m</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Radominski</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Reginster</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Resch</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Roman Ivorra</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Roux</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Vittinghoff</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Austin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Daizadeh</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Bradley</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Grauer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cummings</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Bone</surname>
              <given-names>HG</given-names>
            </name>
          </person-group>
          <article-title>Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension</article-title>
          <source>J Bone Miner Res</source>
          <year>2012</year>
          <volume>27</volume>
          <fpage>694</fpage>
          <lpage>701</lpage>
          <pub-id pub-id-type="doi">10.1002/jbmr.1479</pub-id>
          <pub-id pub-id-type="pmid">22113951</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
